The following is a summary of “Sodium-glucose cotransporter 2 inhibitors and glaucoma in patients with type 2 diabetes,” ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on INSM stock, giving a Buy rating on November 5. Graig ...

Egypt: A recent randomized controlled trial has demonstrated that sitagliptin, a DPP-4 inhibitor, significantly improves ...

And for Takeda's alogliptin, a dipeptidyl peptidase 4 inhibitor for type 2 diabetes, the PDUFA date was extended from October 2008 to June 2009. Although big pharma may be able to bear the ...

Researchers from the US have shown that combination therapy with sitagliptin and metformin results in a substantial and additive glycemic improvement in patients with type 2 diabetes. Sitagliptin ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

β-cell–Centric Construct: A Potential Model for the Classification of DM Given the above discussion, the issue is not "what is LADA" or any clinical presentation of DM under the current system.

Grapefruit can interact with many medications, potentially affecting the way they work or increasing side effects. Some of ...

Semaglutide, the active ingredient in the diabetes and weight loss drugs Ozempic and Wegovy, could lower the risk for ...

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Insmed (INSM – Research Report), with a price ...

It’s the active ingredient in Novo Nordisk’s Ozempic and Wegovy; Study done in comparison of seven popular diabetes medicines ...